Indrayani Biotech Limited has announced its financial results for the fiscal year ended March 31, 2026. The company reported a consolidated net profit of ₹216.03 Lakhs, marking a substantial increase of 135.37% compared to the previous fiscal year’s loss of ₹610.75 Lakhs. Consolidated income for FY26 stood at ₹14,240.35 Lakhs, an increase of 6.79%.
Strong Financial Performance in FY26
Indrayani Biotech Limited has declared robust financial results for the fiscal year ended March 31, 2026. The company achieved a consolidated net profit of ₹216.03 Lakhs, demonstrating a significant turnaround and an impressive increase of 135.37% from the net loss of ₹610.75 Lakhs reported in the previous fiscal year (FY2024-25).
Key Financial Highlights
Consolidated income for the financial year 2025-26 reached ₹14,240.35 Lakhs, reflecting a growth of 6.79% over the previous year. This improved performance is a testament to the company’s strategic initiatives and operational efficiencies.
Standalone Performance
On a standalone basis, the company’s income for FY2025-26 was ₹2,611.03 Lakhs, a decrease of 36.76% from the previous year. The standalone net profit after tax stood at ₹69.97 Lakhs, down by 51.62% compared to FY2024-25. The company continues to focus on reducing operating costs and enhancing efficiencies.
Source: BSE
